Abstract
Colorectal cancer is one of the major contributors to cancer-related mortality in the world. Effective population-based screening for colorectal cancer could prevent the development of cancers through the detection of premalignant adenomas, from which at least 80% of sporadic cancers are thought to arise. Existing screening methods include fecal immunochemical testing, which suffers from low accuracy for adenoma detection, and colonoscopy, which is invasive. Measuring the methylation status of the tumor-derived portion of the cell-free DNA in plasma could offer a non-invasive, accurate and high adherence approach for detecting advanced adenomas, helping potentially to decrease colon cancer mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
